Needham & Company LLC Reiterates Buy Rating for Autolus Therapeutics (NASDAQ:AUTL)

Autolus Therapeutics (NASDAQ:AUTLGet Free Report)‘s stock had its “buy” rating restated by research analysts at Needham & Company LLC in a note issued to investors on Monday, Benzinga reports. They presently have a $9.00 target price on the stock. Needham & Company LLC’s target price would suggest a potential upside of 130.77% from the company’s current price.

A number of other analysts have also recently commented on the stock. Truist Financial upped their target price on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, April 9th. William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a report on Monday, June 3rd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.70.

Read Our Latest Research Report on AUTL

Autolus Therapeutics Stock Down 9.5 %

Shares of Autolus Therapeutics stock opened at $3.90 on Monday. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -3.25 and a beta of 2.02. The company’s 50 day moving average is $4.24 and its 200 day moving average is $5.36. Autolus Therapeutics has a twelve month low of $2.01 and a twelve month high of $7.45.

Autolus Therapeutics (NASDAQ:AUTLGet Free Report) last issued its quarterly earnings data on Friday, May 17th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.14). The company had revenue of $10.09 million for the quarter, compared to the consensus estimate of $50.00 million. During the same quarter last year, the business posted ($0.23) EPS. Sell-side analysts expect that Autolus Therapeutics will post -0.78 EPS for the current fiscal year.

Institutional Trading of Autolus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of AUTL. Rathbones Group PLC purchased a new stake in shares of Autolus Therapeutics in the third quarter worth $171,000. Lynx1 Capital Management LP purchased a new stake in shares of Autolus Therapeutics in the third quarter worth $3,176,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Autolus Therapeutics in the third quarter worth $679,000. Affinity Asset Advisors LLC increased its stake in shares of Autolus Therapeutics by 25.4% in the third quarter. Affinity Asset Advisors LLC now owns 1,992,466 shares of the company’s stock worth $4,642,000 after purchasing an additional 403,449 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its stake in Autolus Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 48,849 shares of the company’s stock valued at $315,000 after acquiring an additional 12,387 shares in the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

(Get Free Report)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

Recommended Stories

Analyst Recommendations for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.